FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $8,020 | +143.8% | 1,407 | +331.6% | 0.00% | – |
| Q4 2022 | $3,289 | -34.2% | 326 | +57.5% | 0.00% | -100.0% |
| Q3 2022 | $5,000 | -16.7% | 207 | -11.9% | 0.00% | 0.0% |
| Q2 2022 | $6,000 | -14.3% | 235 | +23.7% | 0.00% | 0.0% |
| Q1 2022 | $7,000 | -78.8% | 190 | -65.8% | 0.00% | -80.0% |
| Q4 2021 | $33,000 | +1550.0% | 556 | +1444.4% | 0.01% | +400.0% |
| Q3 2021 | $2,000 | -33.3% | 36 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,000 | -50.0% | 36 | -47.8% | 0.00% | 0.0% |
| Q1 2021 | $6,000 | +100.0% | 69 | +91.7% | 0.00% | 0.0% |
| Q4 2020 | $3,000 | – | 36 | +200.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 12 | -97.7% | 0.00% | -100.0% |
| Q2 2020 | $18,000 | +1700.0% | 512 | +1090.7% | 0.01% | – |
| Q1 2020 | $1,000 | -97.4% | 43 | -97.8% | 0.00% | -100.0% |
| Q4 2019 | $39,000 | – | 2,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |